Amneal Pharmaceuticals (AMRX)
(Delayed Data from NSDQ)
$8.49 USD
+0.02 (0.24%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $8.48 -0.01 (-0.12%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.49 USD
+0.02 (0.24%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $8.48 -0.01 (-0.12%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth F Momentum B VGM
Zacks News
Zogenix Gets FDA Nod for Dravet Syndrome Seizure Treatment
by Zacks Equity Research
Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.
Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate
by Zacks Equity Research
Onconova (ONTX) starts investigator-initiated phase I/IIa study of oral rigosertib plus Bristol-Myers Squibb's Opdivo in advanced metastatic KRAS-mutated lung adenocarcinoma.
AMRX vs. COLL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMRX vs. COLL: Which Stock Is the Better Value Option?
Jazz Pharmaceuticals (JAZZ) in Focus: Stock Moves 5.6% Higher
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Moving Average Crossover Alert: Amneal Pharmaceuticals
by Zacks Equity Research
Amneal Pharmaceuticals, Inc. (AMRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Actinium Pharmaceuticals (ATNM) Jumps: Stock Rises 6.7%
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Amneal's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Amneal Pharmaceuticals.
AMRX or COLL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMRX vs. COLL: Which Stock Is the Better Value Option?
New Strong Buy Stocks For May 26th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
AMRX or COLL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMRX vs. COLL: Which Stock Is the Better Value Option?
Amneal (AMRX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Amneal (AMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amneal's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Amneal Pharmaceuticals.
Company News for May 12, 2020
by Zacks Equity Research
Companies In The News Are:
Amneal Pharmaceuticals (AMRX) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 150.00% and 12.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Amneal (AMRX) This Earnings Season?
by Zacks Equity Research
Amneal (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals (AMRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amneal Pharmaceuticals (AMRX) stock based on the movements in the options market lately.
Amneal (AMRX) Catches Eye: Stock Jumps 6.7%
by Zacks Equity Research
Amneal (AMRX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 60.00% and 3.30%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
AMRX vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMRX vs. ZTS: Which Stock Is the Better Value Option?
Amneal Pharmaceuticals Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Amneal Pharmaceuticals
Prospects Appear Bright for Small Drug Industry in 2020
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity keep small drugmakers afloat in a competitive market.
Should Value Investors Pick Amneal Pharma (AMRX) Stock Now?
by Zacks Equity Research
Let's see if Amneal Pharmaceuticals (AMRX) stock is a good choice for value-oriented investors right now from multiple angles.
AMRX vs. NBIX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMRX vs. NBIX: Which Stock Is the Better Value Option?
Company News for Dec 13, 2019
by Zacks Equity Research
Companies in the news are: FB, AMRX, LMPX, TNXP
Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals (AMRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amneal Pharmaceuticals (AMRX) stock based on the movements in the options market lately.